Blog
Machine intelligence and legal contracts: why now?
Machine intelligence applied to the law is not a new concept – yet its gestation has been slow, and it has not inflected into widespread adoption.
Preclinical drug discovery: does software eat the CRO?
The productivity of pharmaceutical research and development has been on the decline for decades. In fact, reports indicate a negative rate of return for many recently developed drugs.
A new operating system for work: our investment in Qatalog
What will be the operations software to power the modern connected organisation? After several years asking this question, meeting Tariq Rauf in July 2019 was an epiphany.
Procurement software: crossing the chasm
Machine intelligence is permeating into more enterprise functions than ever...
Smarter hiring in a post-COVID world
Why now? Poor hiring decisions are costly and time-consuming - and now there's an acute problem to be solved
Tech and the new normal
We've heard a lot about "the new normal" but what does that mean for tech?
What comes after Zoom?
We had video calls in science fiction, and we had video conferencing in the 1990s, just as the web was taking off..
Privacy: from compliance to competitive advantage
Last month, GDPR celebrated its second birthday...
Why we invested in Keelvar
If you've ever sold to large enterprises, we suspect you've felt the pain of procurement...
COVID-19, the future of work, and second-order thinking
COVID-19 is an immense human tragedy...
Rethinking retirement: the next generation of pensions
When reading about the state of retirement savings in Europe, one often encounters the journalistic trope of a 'time bomb'
Why we invested in Mavenoid
Tech support for physical products is a huge market. Any enterprise that ships a manual with their product is a potential Mavenoid customer, as are companies that employ field service engineers to repair hardware and software....
Genomic opportunities, part I: seeking the secrets of life
We have discovered the secret of life! Ever since Francis Crick burst into The Eagle pub one February afternoon in 1953...
Why we invested in Shipamax
Shipamax announced their $7M Series A last week, so we thought we'd share why Mosaic is excited to be leading the financing...
Introducing Mosaic's New Partner, Bart Dessaint
We are blessed to partner with great founders to build breakthrough startups.
Podcast: Adaptive oncology with Dr. Jack Kreindler
Like fingerprints, no two cancers are exactly the same. And yet cancer care - especially for those in the most advanced stages, and with the most complex cases - is administered according to standard, linear protocols.
Book review: Walking with Destiny by Andrew Roberts
There are more than 1,000 biographies that have been written about Winston Churchill!